Optimization of lymphapheresis for manufacturing autologous CAR-T cells
Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures for lymphapheresis for each patient is critical because patients often have progressive diseases and receive medications that cou...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2021-10, Vol.114 (4), p.449-458 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 458 |
|---|---|
| container_issue | 4 |
| container_start_page | 449 |
| container_title | International journal of hematology |
| container_volume | 114 |
| creator | Yamanaka, Ikumi Yamauchi, Takuji Henzan, Tomoko Sakoda, Teppei Miyamoto, Kyoko Mishima, Hiroyuki Ono, Hiroaki Koga, Yuhki Nakashima, Yasuhiro Kato, Koji Miyamoto, Toshihiro Mizuno, Shinichi Ogawa, Yoshihiro Ohga, Shouichi Akashi, Koichi Maeda, Takahiro Kunisaki, Yuya |
| description | Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures for lymphapheresis for each patient is critical because patients often have progressive diseases and receive medications that could reduce T cell counts. We conducted a retrospective study of clinical data from 28 patients who underwent lymphapheresis for CD19-directed CAR-T therapy with tisagenlecleucel to identify factors that could affect CD3+ lymphocyte yields. The numbers of CD3+ cells in peripheral blood were significantly correlated with CD3+ cell yields (correlation coefficient
r
= 0.84), which enabled us to estimate the volume of blood to process before apheresis. We also found that small cell ratio (SCR) at the apheresis site precisely reflected the proportion of lymphocytes, especially in patients without circulating blasts (coefficient of determination:
r
2
= 0.9). We were able to predict the CD3+ cell yield and prevent excessive apheresis by measuring pre-apheresis circulating CD3+ cell counts and monitoring SCR. Collectively, these results will help us to establish a strategy for optimization of lymphapheresis procedures for CAR-T cell production on a patient-by-patient basis. |
| doi_str_mv | 10.1007/s12185-021-03191-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2553238516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2570668307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-23efd6e2e1de55882a9021fb128d8c1a06acff373eb639581f039aa8d0183dc83</originalsourceid><addsrcrecordid>eNp9kE9LwzAYh4MoOKdfwFPBi5do3mT50-MYOoXBQOY5ZG2ydbRNTVrY_PRmThA8eHovz-_l4UHoFsgDECIfI1BQHBMKmDDIAe_P0AiU4JhJOTlHI5JTjrkEcomuYtwRApJM5AjNl11fNdWn6SvfZt5l9aHptqbb2mBjFTPnQ9aYdnCm6IdQtZvMDL2v_cYPMZtN3_AqK2xdx2t04Uwd7c3PHaP356fV7AUvlvPX2XSBCyZFjymzrhSWWigt50pRkydntwaqSlWAIcIUzjHJ7FqwnCtwhOXGqJKAYmWh2Bjdn_52wX8MNva6qeLRwLQ2KWnKOaNMcRAJvfuD7vwQ2mSXKEmEUIzIRNETVQQfY7BOd6FqTDhoIPrYVp_a6uSpv9vqfRqx0yh2xyY2_L7-Z_UF3k98sQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570668307</pqid></control><display><type>article</type><title>Optimization of lymphapheresis for manufacturing autologous CAR-T cells</title><source>Springer Nature - Complete Springer Journals</source><creator>Yamanaka, Ikumi ; Yamauchi, Takuji ; Henzan, Tomoko ; Sakoda, Teppei ; Miyamoto, Kyoko ; Mishima, Hiroyuki ; Ono, Hiroaki ; Koga, Yuhki ; Nakashima, Yasuhiro ; Kato, Koji ; Miyamoto, Toshihiro ; Mizuno, Shinichi ; Ogawa, Yoshihiro ; Ohga, Shouichi ; Akashi, Koichi ; Maeda, Takahiro ; Kunisaki, Yuya</creator><creatorcontrib>Yamanaka, Ikumi ; Yamauchi, Takuji ; Henzan, Tomoko ; Sakoda, Teppei ; Miyamoto, Kyoko ; Mishima, Hiroyuki ; Ono, Hiroaki ; Koga, Yuhki ; Nakashima, Yasuhiro ; Kato, Koji ; Miyamoto, Toshihiro ; Mizuno, Shinichi ; Ogawa, Yoshihiro ; Ohga, Shouichi ; Akashi, Koichi ; Maeda, Takahiro ; Kunisaki, Yuya</creatorcontrib><description>Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures for lymphapheresis for each patient is critical because patients often have progressive diseases and receive medications that could reduce T cell counts. We conducted a retrospective study of clinical data from 28 patients who underwent lymphapheresis for CD19-directed CAR-T therapy with tisagenlecleucel to identify factors that could affect CD3+ lymphocyte yields. The numbers of CD3+ cells in peripheral blood were significantly correlated with CD3+ cell yields (correlation coefficient
r
= 0.84), which enabled us to estimate the volume of blood to process before apheresis. We also found that small cell ratio (SCR) at the apheresis site precisely reflected the proportion of lymphocytes, especially in patients without circulating blasts (coefficient of determination:
r
2
= 0.9). We were able to predict the CD3+ cell yield and prevent excessive apheresis by measuring pre-apheresis circulating CD3+ cell counts and monitoring SCR. Collectively, these results will help us to establish a strategy for optimization of lymphapheresis procedures for CAR-T cell production on a patient-by-patient basis.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-021-03191-x</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Antigens ; Apheresis ; Blood ; CD19 antigen ; CD3 antigen ; Chimeric antigen receptors ; Correlation coefficient ; Correlation coefficients ; Hematology ; Lymphocytes ; Lymphocytes T ; Manufacturing ; Medicine ; Medicine & Public Health ; Oncology ; Optimization ; Original Article ; Patients ; Peripheral blood ; Yield</subject><ispartof>International journal of hematology, 2021-10, Vol.114 (4), p.449-458</ispartof><rights>Japanese Society of Hematology 2021</rights><rights>Japanese Society of Hematology 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-23efd6e2e1de55882a9021fb128d8c1a06acff373eb639581f039aa8d0183dc83</citedby><cites>FETCH-LOGICAL-c376t-23efd6e2e1de55882a9021fb128d8c1a06acff373eb639581f039aa8d0183dc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-021-03191-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-021-03191-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids></links><search><creatorcontrib>Yamanaka, Ikumi</creatorcontrib><creatorcontrib>Yamauchi, Takuji</creatorcontrib><creatorcontrib>Henzan, Tomoko</creatorcontrib><creatorcontrib>Sakoda, Teppei</creatorcontrib><creatorcontrib>Miyamoto, Kyoko</creatorcontrib><creatorcontrib>Mishima, Hiroyuki</creatorcontrib><creatorcontrib>Ono, Hiroaki</creatorcontrib><creatorcontrib>Koga, Yuhki</creatorcontrib><creatorcontrib>Nakashima, Yasuhiro</creatorcontrib><creatorcontrib>Kato, Koji</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><creatorcontrib>Mizuno, Shinichi</creatorcontrib><creatorcontrib>Ogawa, Yoshihiro</creatorcontrib><creatorcontrib>Ohga, Shouichi</creatorcontrib><creatorcontrib>Akashi, Koichi</creatorcontrib><creatorcontrib>Maeda, Takahiro</creatorcontrib><creatorcontrib>Kunisaki, Yuya</creatorcontrib><title>Optimization of lymphapheresis for manufacturing autologous CAR-T cells</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><description>Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures for lymphapheresis for each patient is critical because patients often have progressive diseases and receive medications that could reduce T cell counts. We conducted a retrospective study of clinical data from 28 patients who underwent lymphapheresis for CD19-directed CAR-T therapy with tisagenlecleucel to identify factors that could affect CD3+ lymphocyte yields. The numbers of CD3+ cells in peripheral blood were significantly correlated with CD3+ cell yields (correlation coefficient
r
= 0.84), which enabled us to estimate the volume of blood to process before apheresis. We also found that small cell ratio (SCR) at the apheresis site precisely reflected the proportion of lymphocytes, especially in patients without circulating blasts (coefficient of determination:
r
2
= 0.9). We were able to predict the CD3+ cell yield and prevent excessive apheresis by measuring pre-apheresis circulating CD3+ cell counts and monitoring SCR. Collectively, these results will help us to establish a strategy for optimization of lymphapheresis procedures for CAR-T cell production on a patient-by-patient basis.</description><subject>Antigens</subject><subject>Apheresis</subject><subject>Blood</subject><subject>CD19 antigen</subject><subject>CD3 antigen</subject><subject>Chimeric antigen receptors</subject><subject>Correlation coefficient</subject><subject>Correlation coefficients</subject><subject>Hematology</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Manufacturing</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Optimization</subject><subject>Original Article</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Yield</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE9LwzAYh4MoOKdfwFPBi5do3mT50-MYOoXBQOY5ZG2ydbRNTVrY_PRmThA8eHovz-_l4UHoFsgDECIfI1BQHBMKmDDIAe_P0AiU4JhJOTlHI5JTjrkEcomuYtwRApJM5AjNl11fNdWn6SvfZt5l9aHptqbb2mBjFTPnQ9aYdnCm6IdQtZvMDL2v_cYPMZtN3_AqK2xdx2t04Uwd7c3PHaP356fV7AUvlvPX2XSBCyZFjymzrhSWWigt50pRkydntwaqSlWAIcIUzjHJ7FqwnCtwhOXGqJKAYmWh2Bjdn_52wX8MNva6qeLRwLQ2KWnKOaNMcRAJvfuD7vwQ2mSXKEmEUIzIRNETVQQfY7BOd6FqTDhoIPrYVp_a6uSpv9vqfRqx0yh2xyY2_L7-Z_UF3k98sQ</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Yamanaka, Ikumi</creator><creator>Yamauchi, Takuji</creator><creator>Henzan, Tomoko</creator><creator>Sakoda, Teppei</creator><creator>Miyamoto, Kyoko</creator><creator>Mishima, Hiroyuki</creator><creator>Ono, Hiroaki</creator><creator>Koga, Yuhki</creator><creator>Nakashima, Yasuhiro</creator><creator>Kato, Koji</creator><creator>Miyamoto, Toshihiro</creator><creator>Mizuno, Shinichi</creator><creator>Ogawa, Yoshihiro</creator><creator>Ohga, Shouichi</creator><creator>Akashi, Koichi</creator><creator>Maeda, Takahiro</creator><creator>Kunisaki, Yuya</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20211001</creationdate><title>Optimization of lymphapheresis for manufacturing autologous CAR-T cells</title><author>Yamanaka, Ikumi ; Yamauchi, Takuji ; Henzan, Tomoko ; Sakoda, Teppei ; Miyamoto, Kyoko ; Mishima, Hiroyuki ; Ono, Hiroaki ; Koga, Yuhki ; Nakashima, Yasuhiro ; Kato, Koji ; Miyamoto, Toshihiro ; Mizuno, Shinichi ; Ogawa, Yoshihiro ; Ohga, Shouichi ; Akashi, Koichi ; Maeda, Takahiro ; Kunisaki, Yuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-23efd6e2e1de55882a9021fb128d8c1a06acff373eb639581f039aa8d0183dc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Apheresis</topic><topic>Blood</topic><topic>CD19 antigen</topic><topic>CD3 antigen</topic><topic>Chimeric antigen receptors</topic><topic>Correlation coefficient</topic><topic>Correlation coefficients</topic><topic>Hematology</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Manufacturing</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Optimization</topic><topic>Original Article</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Yield</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamanaka, Ikumi</creatorcontrib><creatorcontrib>Yamauchi, Takuji</creatorcontrib><creatorcontrib>Henzan, Tomoko</creatorcontrib><creatorcontrib>Sakoda, Teppei</creatorcontrib><creatorcontrib>Miyamoto, Kyoko</creatorcontrib><creatorcontrib>Mishima, Hiroyuki</creatorcontrib><creatorcontrib>Ono, Hiroaki</creatorcontrib><creatorcontrib>Koga, Yuhki</creatorcontrib><creatorcontrib>Nakashima, Yasuhiro</creatorcontrib><creatorcontrib>Kato, Koji</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><creatorcontrib>Mizuno, Shinichi</creatorcontrib><creatorcontrib>Ogawa, Yoshihiro</creatorcontrib><creatorcontrib>Ohga, Shouichi</creatorcontrib><creatorcontrib>Akashi, Koichi</creatorcontrib><creatorcontrib>Maeda, Takahiro</creatorcontrib><creatorcontrib>Kunisaki, Yuya</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamanaka, Ikumi</au><au>Yamauchi, Takuji</au><au>Henzan, Tomoko</au><au>Sakoda, Teppei</au><au>Miyamoto, Kyoko</au><au>Mishima, Hiroyuki</au><au>Ono, Hiroaki</au><au>Koga, Yuhki</au><au>Nakashima, Yasuhiro</au><au>Kato, Koji</au><au>Miyamoto, Toshihiro</au><au>Mizuno, Shinichi</au><au>Ogawa, Yoshihiro</au><au>Ohga, Shouichi</au><au>Akashi, Koichi</au><au>Maeda, Takahiro</au><au>Kunisaki, Yuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of lymphapheresis for manufacturing autologous CAR-T cells</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><date>2021-10-01</date><risdate>2021</risdate><volume>114</volume><issue>4</issue><spage>449</spage><epage>458</epage><pages>449-458</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures for lymphapheresis for each patient is critical because patients often have progressive diseases and receive medications that could reduce T cell counts. We conducted a retrospective study of clinical data from 28 patients who underwent lymphapheresis for CD19-directed CAR-T therapy with tisagenlecleucel to identify factors that could affect CD3+ lymphocyte yields. The numbers of CD3+ cells in peripheral blood were significantly correlated with CD3+ cell yields (correlation coefficient
r
= 0.84), which enabled us to estimate the volume of blood to process before apheresis. We also found that small cell ratio (SCR) at the apheresis site precisely reflected the proportion of lymphocytes, especially in patients without circulating blasts (coefficient of determination:
r
2
= 0.9). We were able to predict the CD3+ cell yield and prevent excessive apheresis by measuring pre-apheresis circulating CD3+ cell counts and monitoring SCR. Collectively, these results will help us to establish a strategy for optimization of lymphapheresis procedures for CAR-T cell production on a patient-by-patient basis.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><doi>10.1007/s12185-021-03191-x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2021-10, Vol.114 (4), p.449-458 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2553238516 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Antigens Apheresis Blood CD19 antigen CD3 antigen Chimeric antigen receptors Correlation coefficient Correlation coefficients Hematology Lymphocytes Lymphocytes T Manufacturing Medicine Medicine & Public Health Oncology Optimization Original Article Patients Peripheral blood Yield |
| title | Optimization of lymphapheresis for manufacturing autologous CAR-T cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A50%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20lymphapheresis%20for%20manufacturing%20autologous%20CAR-T%20cells&rft.jtitle=International%20journal%20of%20hematology&rft.au=Yamanaka,%20Ikumi&rft.date=2021-10-01&rft.volume=114&rft.issue=4&rft.spage=449&rft.epage=458&rft.pages=449-458&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-021-03191-x&rft_dat=%3Cproquest_cross%3E2570668307%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570668307&rft_id=info:pmid/&rfr_iscdi=true |